Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling
Hye-Min Jeon, … , Do-Hyun Nam, Jeongwu Lee
Hye-Min Jeon, … , Do-Hyun Nam, Jeongwu Lee
Published October 3, 2023
Citation Information: JCI Insight. 2023;8(21):e167049. https://doi.org/10.1172/jci.insight.167049.
View: Text | PDF
Research Article Development Oncology

The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling

  • Text
  • PDF
Abstract

Glioblastoma (GBM) is the most lethal brain cancer with a dismal prognosis. Stem-like GBM cells (GSCs) are a major driver of GBM propagation and recurrence; thus, understanding the molecular mechanisms that promote GSCs may lead to effective therapeutic approaches. Through in vitro clonogenic growth-based assays, we determined mitogenic activities of the ligand molecules that are implicated in neural development. We have identified that semaphorin 3A (Sema3A), originally known as an axon guidance molecule in the CNS, promotes clonogenic growth of GBM cells but not normal neural progenitor cells (NPCs). Mechanistically, Sema3A binds to its receptor neuropilin-1 (NRP1) and facilitates an interaction between NRP1 and TGF-β receptor 1 (TGF-βR1), which in turn leads to activation of canonical TGF-β signaling in both GSCs and NPCs. TGF-β signaling enhances self-renewal and survival of GBM tumors through induction of key stem cell factors, but it evokes cytostatic responses in NPCs. Blockage of the Sema3A/NRP1 axis via shRNA-mediated knockdown of Sema3A or NRP1 impeded clonogenic growth and TGF-β pathway activity in GSCs and inhibited tumor growth in vivo. Taken together, these findings suggest that the Sema3A/NRP1/TGF-βR1 signaling axis is a critical regulator of GSC propagation and a potential therapeutic target for GBM.

Authors

Hye-Min Jeon, Yong Jae Shin, Jaehyun Lee, Nakho Chang, Dong-Hun Woo, Won Jun Lee, Dayna Nguyen, Wonyoung Kang, Hee Jin Cho, Heekyoung Yang, Jin-Ku Lee, Jason K. Sa, Yeri Lee, Dong Geon Kim, Benjamin W. Purow, Yeup Yoon, Do-Hyun Nam, Jeongwu Lee

×

Figure 6

NRP1hi GBM cells are enriched with clonogenicity and TGF-β activity.

Options: View larger image (or click on image) Download as PowerPoint
NRP1hi GBM cells are enriched with clonogenicity and TGF-β activity.
(A)...
(A) Left, t-distributed stochastic neighbor embedding (t-SNE) plots of GBM single cells (131, 352, and 827; total of 31,255 cells). Color gradient was overlaid with NRP1 (blue), TGF-β (green), and stemness (red) signature scores. Right, quantitation of TGF-β and stemness gene set expression in NRP1hi cells and NRP1lo/– GBM cells: 131, 352, and 827. Internal line represents median value. *P < 0.0001 by Mann-Whitney test. (B) FACS-based segregation of NRP1hi and NRP1lo/– cells from GBM tumors. (C) IBs of NRP1, p-SMAD2, and SMAD2 in NRP1hi and NRP1lo/– cells derived from primary GBM tumor 096. (D) Relative levels of Sox4, ID1, and ID3 in NRP1hi cells and NRP1lo/– GBM cells (096). Data represent mean ± SD. *P < 0.01 by 1-way ANOVA. (E) LDA analysis of NRP1hi and NRP1lo/– cells derived from GBM tumors (096 and 131). Estimated frequency of clonogenic cells in each subpopulation was calculated by extreme LDA. *P < 0.01 by pairwise t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts